These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 35222422)

  • 1. T Cell Recognition of Tumor Neoantigens and Insights Into T Cell Immunotherapy.
    Sim MJW; Sun PD
    Front Immunol; 2022; 13():833017. PubMed ID: 35222422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity.
    Mariuzza RA; Wu D; Pierce BG
    Front Immunol; 2023; 14():1303304. PubMed ID: 38045695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
    Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
    Bai P; Li Y; Zhou Q; Xia J; Wei PC; Deng H; Wu M; Chan SK; Kappler JW; Zhou Y; Tran E; Marrack P; Yin L
    Oncoimmunology; 2021 Jan; 10(1):1868130. PubMed ID: 33537173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen.
    Chen P; Chen D; Bu D; Gao J; Qin W; Deng K; Ren L; She S; Xu W; Yang Y; Xie X; Liao W; Chen H
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37076248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
    Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD
    Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
    Roerden M; Nelde A; Walz JS
    Front Immunol; 2019; 10():3004. PubMed ID: 31921218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma.
    Bräunlein E; Lupoli G; Füchsl F; Abualrous ET; de Andrade Krätzig N; Gosmann D; Wietbrock L; Lange S; Engleitner T; Lan H; Audehm S; Effenberger M; Boxberg M; Steiger K; Chang Y; Yu K; Atay C; Bassermann F; Weichert W; Busch DH; Rad R; Freund C; Antes I; Krackhardt AM
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoantigens in Hematologic Malignancies.
    Biernacki MA; Bleakley M
    Front Immunol; 2020; 11():121. PubMed ID: 32117272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants for Neoantigen Identification.
    Garcia-Garijo A; Fajardo CA; Gros A
    Front Immunol; 2019; 10():1392. PubMed ID: 31293573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
    Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
    J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of U2AF1 neoantigens in myeloid neoplasms.
    Biernacki MA; Lok J; Black RG; Foster KA; Cummings C; Woodward KB; Monahan T; Oehler VG; Stirewalt DL; Wu D; Rongvaux A; Deeg HJ; Bleakley M
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38164756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
    Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines.
    Roesler AS; Anderson KS
    Methods Mol Biol; 2022; 2410():649-670. PubMed ID: 34914074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen.
    Wu D; Gallagher DT; Gowthaman R; Pierce BG; Mariuzza RA
    Nat Commun; 2020 Jun; 11(1):2908. PubMed ID: 32518267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations.
    Shen M; Chen S; Han X; Hao Y; Wang J; Li L; Chen T; Wang B; Zou L; Zhang T; Zhang W; Han X; Wang W; Yu H; Li K; Liu S; Jin A
    Cancer Immunol Immunother; 2024 Jun; 73(8):150. PubMed ID: 38832948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational Prediction and Validation of Tumor-Associated Neoantigens.
    Roudko V; Greenbaum B; Bhardwaj N
    Front Immunol; 2020; 11():27. PubMed ID: 32117226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoantigens - the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders.
    Sabdia MB; Patch AM; Tsang H; Gandhi MK
    Blood Rev; 2022 Nov; 56():100969. PubMed ID: 35570070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.